-
公开(公告)号：KR1020090012416A
公开(公告)日：2009-02-04
申请号：KR1020070076217
申请日：2007-07-30
Applicant: 재단법인서울대학교산학협력재단 , 중앙대학교 산학협력단
Abstract: A pharmaceutical composition is provided to increase transcriptional activity of p53 and cell death by hindering analysis of p53 by MDM2 and to have anticancer effect suppressing dysplasia and carcinogenesis of cell. A pharmaceutical composition shows anticancer effect by including p19Ras protein as active component, uniting p19Ras protein with p53 protein and increasing activity of the p53 protein. The p19Ras protein is indicated as amino acid sequence of a sequence listing sequence number 1. The cancer is breast cancer, ovarian cancer, liver cancer, lung cancer, colon carcinoma or prostate cancer. An activity of the p53 protein is increased by hindering ubiquitination of p53 by MDM2.
Abstract translation: 提供药物组合物，通过抑制MDM2对p53的分析和抑制细胞发育不良和致癌作用具有抗癌作用，增加p53的转录活性和细胞死亡。 药物组合物通过包括p19Ras蛋白作为活性成分显示抗癌作用，将p19Ras蛋白与p53蛋白质结合并增加p53蛋白的活性。 p19Ras蛋白被表示为序列表序列号1的氨基酸序列。癌症是乳腺癌，卵巢癌，肝癌，肺癌，结肠癌或前列腺癌。 通过抑制MDM2对p53的泛素化，p53蛋白的活性增加。
-
公开(公告)号：KR101145061B1
公开(公告)日：2012-05-11
申请号：KR1020070076217
申请日：2007-07-30
Applicant: 재단법인서울대학교산학협력재단 , 중앙대학교 산학협력단
Abstract: A pharmaceutical composition is provided to increase transcriptional activity of p53 and cell death by hindering analysis of p53 by MDM2 and to have anticancer effect suppressing dysplasia and carcinogenesis of cell. A pharmaceutical composition shows anticancer effect by including p19Ras protein as active component, uniting p19Ras protein with p53 protein and increasing activity of the p53 protein. The p19Ras protein is indicated as amino acid sequence of a sequence listing sequence number 1. The cancer is breast cancer, ovarian cancer, liver cancer, lung cancer, colon carcinoma or prostate cancer. An activity of the p53 protein is increased by hindering ubiquitination of p53 by MDM2.
-
Search Results
2
records
(took 0.024 seconds)
